Dyadic International, Inc. (DYAI) is a publicly traded Healthcare sector company. As of July 7, 2026, DYAI trades at $1.13 with a market cap of $34.27M and a P/E ratio of -4.22. DYAI moved +18.85% today. Year to date, DYAI is +10.36%; over the trailing twelve months it is +2.94%. Its 52-week range spans $0.65 to $2.20. Analyst consensus is buy with an average price target of $0.00. Rallies surfaces DYAI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Dyadic Secures $3.1M Gates Grant; C1 Platform Achieves 15-Day Protein Production: Dyadic International received the final $738,743 payment of a $3.1 million Gates Foundation grant for RSV and malaria monoclonal antibody programs, with C1 demonstrating yields and neutralization comparable to CHO systems. In a $4.5 million CEPI/FBS collaboration, C1 achieved plasmid-to-protein production in about 15 days.
| Metric | Value |
|---|---|
| Price | $1.13 |
| Market Cap | $34.27M |
| P/E Ratio | -4.22 |
| EPS | $-0.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.20 |
| 52-Week Low | $0.65 |
| Volume | 662.90K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.09M |
| Net Income | $-7.36M |
| Gross Margin | 24.93% |
1 analysts cover DYAI: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $0.00.